8 results about "Vitamin analog" patented technology

The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

The present disclosure provides novel Vitamin D analogs, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly melanoma, ovarian, and breast cancers. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

The application discloses application of PAK4 inhibitor comp55 in preparation of a medicine for inhibiting formation of tumor-related fibroblasts, and belongs to the technical field of medicine application. The application first proposes the application of PAK4 inhibitor comp55 in preparation of the medicine for inhibiting formation of tumor-related fibroblasts, and provides a new scheme for the medicine for inhibiting formation of tumor-related fibroblasts. The application first proposes that PAK4 inhibitor comp55 inhibits formation of CAFs by targeting PAK4. The application first proposes that PAK4 inhibitor comp55 and vitamin D analogues are used in combination to synergistically inhibit formation of CAFs. The application first proposes that PAK4 inhibitor comp55 and anti-PD-1 antibodies are used in combination to synergistically inhibit formation of CAFs. The application first proposes that PAK4 inhibitor comp55, vitamin D analogues and anti-PD-1 antibodies are used in combination to significantly inhibit tumor growth, inhibit formation of CAFs, promote CD8 + T cell infiltration and IFN-gamma secretion.

The present application relates to the field of detection reagent, especially to a vitamin A analogue, a synthesis method and application thereof. The present application provides a vitamin A analogue, a synthesis method and application thereof. The vitamin A analogue has relatively low cost, can be synthesized in large scale, and has certain difference from vitamin A in mass spectrum, and can be used as an internal standard of vitamin A to detect vitamin A.

The present disclosure relates to the topical treatment of skin diseases such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratosis, pachyonychia congenita, multiple sebaceous cysts, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and keratinization disorders using (a) a JAK inhibitor or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

The invention relates to the field of medicines, in particular to a liver cancer treatment medicine composition with a synergistic effect and application of the liver cancer treatment medicine composition in preparation of medicines for treating liver cancer, and the medicine composition is composed of a vitamin D analogue and a PD-1 inhibitor. The pharmaceutical composition disclosed by the invention can amplify cascade reaction of an IFN-gamma signal channel in a tumor and activate anti-tumor immunity, so that the effect of killing liver cancer is achieved; a subcutaneous tumor-bearing model, a liver cancer in-situ model and a liver cancer patient organ respectively prove that the vitamin D analogue paricalcitol can obviously improve the curative effect of the PD-1 inhibitor. The vitamin D analogue paricalcitol is a clinically mature drug, has low drug toxicity, small side effects after long-term use and convenient clinical application, can significantly improve the sensitivity of liver cancer to a PD-1 inhibitor, and provides a new strategy for treatment of liver cancer.

Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and / or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.

The invention discloses a supported photosensitizer as well as a preparation method and application thereof in photocatalysis, and belongs to the technical field of photosensitizers. The preparation method comprises the following steps: A, a reductive amination method: taking chitosan as a raw material, catalyzing with an aromatic aldehyde monomer by adopting acid at room temperature to form a Schiff base, and then reacting with a reducing agent in situ; and B, a nucleophilic substitution method: taking chitosan as a raw material, and carrying out alkylation reaction on the chitosan, an aryl chloromethane monomer and amino on a chitosan chain under alkaline conditions. The supported photosensitizer retains the activity of a homogeneous catalyst in double-bond cis-trans isomerization of vitamin D analogues, and after the reaction is completed, the advantages of separation, recovery, reusability and even continuous flow production can be realized by adding an alcohol solvent in a proper proportion.